A Systems Modeling Approach to the Study of Retinoid Function: Implications for Evaluation of Retinoids in Cancer Chemoprevention and/or Chemotherapy
Author:
Lewis Kevin C.,Hochadel James F.,Zech Loren A.
Reference33 articles.
1. Berman, M., Beltz, W.F., Greif, P.C., Chabay, R., and Boston, R.C., 1983, CONSAM User’s Guide, PHS Publication No. 1983–421-132:3279, U.S. Government Printing Office, Washington, DC. 2. Berman, M., and Weiss, M.F.. 1978, SAAMManual; SAAM27 Version, DHEW Publication No. (NIH) 78–180, U.S. Government Printing Office, Washington, DC. 3. Cobleigh, M.A., Dowlatshahi, K., Deutsch, T.A., Mehta, R.G., Moon, R.C., Minn, F., Benson, A.B., Rademaker, A.W., Ashenhurst, J.B., Wade, J.L., and Walter, J., 1993, Phase I/II trial of Tamoxifen with or without Fenretina-mide, an analog of vitamin A, in women with metastatic breast cancer, J. Clin. Oncol. 11:474–477. 4. Coccheto, D.M., Wargin, W.A., and Crow, J.W., 1980, Pitfalls and valid approaches to pharmacokinetic analysis of mean concentration data following intravenous administration, J. Pharmacokinet. Biopharm. 8:539–552. 5. Costa, A., Malone, W., Perloff, M., Buranelli, F., Campa, T., Dossena, G., Magni, A., Pizzichetta, M., Andreoli, C, Del Vecchio, M., Formelli, F., and Barberi, A., 1989, Tolerability of the synthetic retinoid Fenretinide (HPR), Europ. J. Cancer Clin. Oncol. 25: 805–808.
|
|